Senolytic supplements and drugs: what actually has human data
Senolytics are supposed to clear out old, damaged cells that build up as we age. A couple of prescription-drug combinations have small human studies behind them; the popular over-the-counter supplement version (fisetin) mostly doesn't.
Senolytics are drugs or compounds designed to selectively clear senescent ("zombie") cells that accumulate with age. Dasatinib plus quercetin (D+Q) is the combination with the most human data — small trials in idiopathic pulmonary fibrosis and diabetic kidney disease showed it reduces senescent-cell markers and improved physical function in one trial. Fisetin, the senolytic most widely sold as a standalone supplement, has no published, adequately powered, placebo-controlled human trial showing a clinical benefit at consumer doses — its basic pharmacokinetics in humans are still being characterised. No senolytic has improved a hard clinical outcome in an adequately powered randomised trial.
- D+Q reduced senescent-cell burden (p16+ and p21+ cells, SASP inflammatory markers) in a nine-person diabetic kidney disease pilot trial — a mechanism result, not a proven clinical outcome, and the sample size is too small to generalise from.
- A separate small D+Q trial in idiopathic pulmonary fibrosis reported improved physical function measures, one of the first human signals that clearing senescent cells might translate to a functional benefit.
- Fisetin, sold widely as an over-the-counter senolytic supplement, lacks any adequately powered, placebo-controlled human trial demonstrating clinical benefit — its pharmacokinetics at the doses typically sold are not well characterised.
- As of 2026, roughly two dozen senolytic-related studies are registered on ClinicalTrials.gov, spanning conditions from Alzheimer's risk to frailty — most are small, early-phase, and not yet reporting results.
- "Reduces markers of senescence" and "improves a disease outcome" are different claims. Every senolytic sold today has, at best, evidence for the first — none has adequately powered evidence for the second.
What each senolytic actually has behind it
Senolytic compounds, ranked by human evidence quality
| Compound | Form | Strongest human evidence | What it does NOT show |
|---|---|---|---|
| Dasatinib + Quercetin (D+Q) | Prescription drug + supplement, combined | Reduced senescent-cell markers in a 9-person diabetic kidney disease pilot; improved physical function measures in a small idiopathic pulmonary fibrosis trial | No adequately powered trial has shown it improves a hard clinical endpoint (mortality, major organ outcome) in any population |
| Fisetin | Over-the-counter supplement | Strong preclinical (mouse) senolytic activity; human pharmacokinetics still being characterised as of 2026 | No published, adequately powered, placebo-controlled human trial showing clinical benefit at the doses commonly sold |
| PCC1 (grape-seed procyanidin C1) | Over-the-counter supplement | Extended overall mouse lifespan by 9.4% and cut mortality hazard 65% (Nature Metabolism, 2021); one 17-person human preprint reporting reduced senescence markers over three days | The mouse result used intraperitoneal injection, not oral dosing; the human preprint is uncontrolled, unpublished and too small to act on |
| Quercetin (alone) | Over-the-counter supplement | Long history of use as a general antioxidant supplement; senolytic activity mainly studied in combination with dasatinib, not alone | No standalone senolytic trial evidence — its role in trials is always paired with dasatinib |
What the actual trials measured
The most-cited human senolytics study gave nine adults with diabetic kidney disease a three-day oral course of dasatinib (100 mg) plus quercetin (1000 mg), then measured senescent-cell markers 11 days later. Adipose and epidermal senescent-cell abundance fell, along with p16+ and p21+ cell counts and circulating inflammatory SASP factors including IL-1α, IL-6 and MMPs. That is a genuine biological signal — the drugs did what they were designed to do at the cellular level — but with nine participants and no placebo control on the biomarker endpoints, it cannot tell you whether clearing those cells changed anyone's actual kidney disease outcome.
A separate small trial of D+Q in idiopathic pulmonary fibrosis (a scarring lung disease) reported improvements in physical function measures, one of the first signals connecting senolytic treatment to something closer to how a patient actually feels or functions, rather than a lab marker alone.
Frequently asked questions
Does fisetin actually work as a senolytic in humans?
It has strong senolytic activity in mouse and cell-culture studies, but there is no published, adequately powered, placebo-controlled human trial showing a clinical benefit from oral fisetin supplementation at the doses typically sold. Its basic human pharmacokinetics — how much of an oral dose is actually absorbed and reaches relevant tissue — are still being characterised as of 2026, which makes it hard to know if consumer doses even approximate what worked in animal studies.
Is dasatinib plus quercetin (D+Q) safe to take for senolytic purposes?
Dasatinib is a prescription cancer chemotherapy drug (a tyrosine kinase inhibitor) with known, sometimes serious side effects at cancer-treatment doses, and it is not approved for senolytic or anti-aging use at any dose. The small trials that used it for senolytic purposes did so under medical supervision at specific, lower short-course doses for a specific patient population — this is not the same as an unsupervised, ongoing off-label senolytic protocol, which carries real risks that haven't been characterised in a healthy population.
How many senolytic trials are currently running?
As of 2026, roughly two dozen senolytic-related studies are registered on ClinicalTrials.gov, spanning conditions including diabetic kidney disease, pulmonary fibrosis, frailty, osteoarthritis and Alzheimer's-risk populations. Most are early-phase and have not yet reported results — the evidence base is expected to grow substantially over the next several years, but is thin today.
Should I take a senolytic supplement now, or wait for more evidence?
That's a personal risk decision this site doesn't make for anyone — but the facts to weigh are: over-the-counter senolytics like fisetin currently have no adequately powered human trial evidence of clinical benefit, prescription-based D+Q protocols have only small, short, biomarker-focused human data, and none of these compounds is approved for this use by any regulator. If you're already taking one, that's information for a conversation with your own physician, not a reason for panic — but "human data exists" and "proven to work" are different claims, and most of what's marketed today is the former dressed as the latter.
Keep reading
- PCC1 and the grape-seed longevity pill: what the study actually showed
The senolytic behind the 2026 "live to 150" headlines, and the injection-versus-capsule problem.
- Is there a pill that can make you live to 150?
Every compound sold on a lifespan promise, ranked on human evidence.
- Anti-Aging Pharma
How senolytics compare to the other drug classes being marketed for aging.
- Biological age tests
The other number the longevity industry sells, graded the same way.
More in Supplements
- PCC1 and the grape-seed longevity pill: what the study actually showed
PCC1 extended mouse lifespan by 9.4% — by injection, starting in old age. Here is the full study, the human data that exists, and what the capsules leave out.
- Best sleep aids, ranked by evidence.
Melatonin has modest evidence for insomnia and strong evidence for jet lag; magnesium, glycine, weighted blankets, valerian and CBD ranked on what each shows.
- Taurine and longevity: what the human evidence actually shows
The study that made taurine famous extended lifespan in mice, not humans. What the actual human trials show, the dose studied, and who should be careful.
- Creatine and aging: the best-documented compound in longevity
Creatine has more human trials than any other longevity supplement, at a fraction of the price. What's proven for aging, the dose, and who should be careful.
- Urolithin A for muscle and mitochondria: what the trials actually show
A 2022 RCT found urolithin A improved muscle strength but missed its primary endpoint. Here's what every human trial actually shows, and what's still unproven.
- Which science-backed supplements can safely extend life?
Correcting vitamin D deficiency ranks first among supplements safely backed by human evidence; NMN, resveratrol and most others lack human trials.